Diethyl 2-(2,2-diethoxyethoxy)propanedioate | 695182-41-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Diethyl 2-(2,2-diethoxyethoxy)propanedioate
• CAS: 695182-41-3
• 化学式: C₁₃H₂₄O₇
• 分子量: 292.329
• InChiKey: RERHFHWETDRFOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  350.2±37.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  80.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Diethyl 2-(2,2-diethoxyethoxy)propanedioate 、 5-ethoxycarbonyl-4-methyl-1,3-thiazol-2-ylguanidine 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 生成 2-[5-(2,2-diethoxy-ethoxy)-4,6-dihydroxy-pyrimidin-2-ylamino]-4-methyl-thiazole-5-carboxylic acid ethyl ester
  参考文献：
  名称：

  Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure–activity relationships

  摘要：

  A series of fused pyrimidine based inhibitors of PDE7 have been derived from an earlier screening lead 1. The synthesis, structure-activity relationships (SAR) and selectivity against several other PDE family members are described. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.025
• 作为产物：
  描述：

  重氮丙酸二乙酯 、 2,2-二乙氧基乙醇 在 rhodium(II) acetate dimer 作用下， 以 甲苯 为溶剂， 以67%的产率得到Diethyl 2-(2,2-diethoxyethoxy)propanedioate
  参考文献：
  名称：

  Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure–activity relationships

  摘要：

  A series of fused pyrimidine based inhibitors of PDE7 have been derived from an earlier screening lead 1. The synthesis, structure-activity relationships (SAR) and selectivity against several other PDE family members are described. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.025

文献信息

• Fused Heterocyclic Compounds and Use Thereof
  申请人：Barbosa Joseph

  公开号：US20080293650A1

  公开（公告）日：2008-11-27

  Fused heterocylic compounds of the following Formula wherein R 1 , R 2 , R 5 , Z, J 1 and J 2 are described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.

  以下式子描述的融合杂环化合物，其中R1、R2、R5、Z、J1和J2在此处描述，并提供了其类似物，可用于治疗白细胞激活相关疾病。
• FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Barbosa Joseph

  公开号：US20110230468A1

  公开（公告）日：2011-09-22

  Fused heterocylic compounds of the following Formula wherein R 1 , R 2 , R 5 , Z, J 1 and J 2 are described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.

  以下式子描述了以下融合杂环化合物：其中R1、R2、R5、Z、J1和J2如下所述，并提供了用于治疗白细胞激活相关疾病的类似物。
• Fused heterocyclic compounds and use thereof
  申请人：——

  公开号：US20040142945A1

  公开（公告）日：2004-07-22

  Fused heterocylic compounds of the following Formula 1 wherein R 1 , R 2 , R 5 , Z, J 1 and J 2 are described herein, and analogs thereof are provided which are useful in treating leukocyte activation-associated disorders.

  下式的融合杂环化合物 1 其中 R 1 , R 2 , R 5 Z, J 1 和 J 2 及其类似物，可用于治疗白细胞活化相关疾病。
• US7384937B2
  申请人：——

  公开号：US7384937B2

  公开（公告）日：2008-06-10
• US7981881B2
  申请人：——

  公开号：US7981881B2

  公开（公告）日：2011-07-19